Wells Fargo & Company Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

Xenon Pharmaceuticals (NASDAQ:XENE) had its price objective boosted by Wells Fargo & Company from $49.00 to $68.00 in a research note published on Tuesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the company. Morgan Stanley set a $97.00 target price on Xenon Pharmaceuticals in a report on Monday. Stifel Nicolaus set a $66.00 price target on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. HC Wainwright upped their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday. Chardan Capital raised Xenon Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, November 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $71.94.

Xenon Pharmaceuticals Trading Down 3.4%

Shares of XENE opened at $60.61 on Tuesday. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $63.95. The firm has a fifty day simple moving average of $42.95 and a 200 day simple moving average of $41.56. The stock has a market capitalization of $5.04 billion, a price-to-earnings ratio of -13.90 and a beta of 0.91.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the previous year, the company earned ($0.84) EPS. As a group, research analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

Insider Transactions at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total value of $1,777,200.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at $266,580. This represents a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.07% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Cinctive Capital Management LP increased its position in shares of Xenon Pharmaceuticals by 1.1% in the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock valued at $1,045,000 after acquiring an additional 263 shares during the period. Arizona State Retirement System boosted its holdings in shares of Xenon Pharmaceuticals by 1.8% during the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after purchasing an additional 334 shares during the period. State of Wyoming grew its stake in shares of Xenon Pharmaceuticals by 30.4% in the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 350 shares during the last quarter. Quarry LP grew its stake in shares of Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 500 shares during the last quarter. Finally, Altfest L J & Co. Inc. increased its holdings in Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 501 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 topline results show azetukalner produced a statistically significant reduction in focal‑onset seizure frequency, positioning the drug for an NDA submission targeted in Q3 2026 — a major clinical milestone that drove the earlier sharp rally. GlobeNewswire: X-TOLE2 Results Reuters: Trial Meets Main Goal
• Positive Sentiment: Multiple brokerages raised price targets and maintained bullish ratings (HC Wainwright, Deutsche Bank, Needham, Wells Fargo, Wedbush), reflecting upwardly revised sales and valuation assumptions after the Phase 3 readout. Benzinga: Analyst Upgrades
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement, indicating the exchange processed material news that subsequently drove heavy intraday activity. (News pending/halt was lifted following the topline release.)
• Neutral Sentiment: Yesterday’s massive intraday rally — driven by the trial news — created rapid re‑rating and higher volatility; that squeeze can produce follow‑through profit‑taking and larger volume swings. 247WallSt: Big One‑Day Gain
• Negative Sentiment: Xenon announced a proposed underwritten public offering of $500M of common shares (with a 30‑day option for an additional $75M). Issuing new equity after a large run‑up creates dilution risk and puts selling pressure on the stock even though proceeds could fund commercialization and ongoing trials. GlobeNewswire: Offering MSN: Offering Coverage

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.